143 related articles for article (PubMed ID: 16539643)
21. Rituximab as treatment for refractory kidney transplant rejection.
Becker YT; Becker BN; Pirsch JD; Sollinger HW
Am J Transplant; 2004 Jun; 4(6):996-1001. PubMed ID: 15147435
[TBL] [Abstract][Full Text] [Related]
22. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
[TBL] [Abstract][Full Text] [Related]
23. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
24. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
[TBL] [Abstract][Full Text] [Related]
25. Antibody-mediated rejection in hand transplantation.
Weissenbacher A; Hautz T; Zelger B; Zelger BG; Mayr V; Brandacher G; Pratschke J; Schneeberger S
Transpl Int; 2014 Feb; 27(2):e13-7. PubMed ID: 24266875
[TBL] [Abstract][Full Text] [Related]
26. Acute cellular rejection with CD20-positive lymphoid clusters in kidney transplant patients following lymphocyte depletion.
Kayler LK; Lakkis FG; Morgan C; Basu A; Blisard D; Tan HP; McCauley J; Wu C; Shapiro R; Randhawa PS
Am J Transplant; 2007 Apr; 7(4):949-54. PubMed ID: 17331114
[TBL] [Abstract][Full Text] [Related]
27. Early and late humoral rejection: a clinicopathologic entity in two times.
Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
[TBL] [Abstract][Full Text] [Related]
28. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report.
Celik A; Saglam F; Cavdar C; Sifil A; Atila K; Sarioglu S; Bora S; Gulay H; Camsari T
Transplant Proc; 2008; 40(1):302-4. PubMed ID: 18261611
[TBL] [Abstract][Full Text] [Related]
29. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
Zarkhin V; Li L; Sarwal MM
Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
[No Abstract] [Full Text] [Related]
30. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
van den Hoogen MW; Kamburova EG; Baas MC; Steenbergen EJ; Florquin S; M Koenen HJ; Joosten I; Hilbrands LB
Am J Transplant; 2015 Feb; 15(2):407-16. PubMed ID: 25612493
[TBL] [Abstract][Full Text] [Related]
31. Rituximab in immunologic glomerular diseases.
Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
33. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Pescovitz MD
Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
[TBL] [Abstract][Full Text] [Related]
34. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
35. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
[TBL] [Abstract][Full Text] [Related]
36. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
[TBL] [Abstract][Full Text] [Related]
37. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
38. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
39. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
40. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.
Scheepstra C; Bemelman FJ; van der Loos C; Rowshani AT; van Donselaar-Van der Pant KA; Idu MM; ten Berge IJ; Florquin S
Transplantation; 2008 Sep; 86(6):772-8. PubMed ID: 18813100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
